by goldfishadmin | Dec 9, 2024 | News
Funding to support preclinical development of Orphagen’s lead IBD candidate, OR-812, a first-in-class, small molecule inhibitor of the retinoic acid receptor alpha (RARα) SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, Inc., a biotech company...
by goldfishadmin | Nov 20, 2024 | News
The Cancer Prevention & Research Institute of Texas (CPRIT) announced today that it plans to award Orphagen a $10.2 M product development grant over three years to partially fund the final steps towards IND filing and a Phase 1 clinical trial of OR-449, a novel...
by goldfishadmin | Jun 11, 2022 | News
SAN DIEGO, June 11, 2022 – Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from...
by goldfishadmin | Aug 31, 2016 | News
Orphagen Pharmaceuticals, Inc., a privately held company, announced today that its partner, Japan Tobacco Inc. (“JT”), has entered Phase I clinical trials with an oral small molecule, JTE-451, for treatment of autoimmune and allergic diseases. This is a major...
by goldfishadmin | Aug 12, 2016 | Pipeline column
Our mission is translational drug discovery and development with novel targets leading to first-in-class industry partnerships....
